NervGen Pharma Corp. (NGEN NASDAQ) stock market data APIs
$1.8008
0.05(2.8%)
as of June 9, 2026
Try our APIs with
free plan!
NervGen Pharma Corp. Financial Data Overview
Price chart is built with
Anychart
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Prev. Close
1.8008
Open
1.8553
High
1.9054
Low
1.7777
52 wk Range
1.765-6.3
Market Cap
198 M
Shares Outstanding
106 M
EPS
-0.0654
Beta
0.878
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NervGen Pharma Corp. data using free add-ons & libraries
Get NervGen Pharma Corp. Fundamental Data
NervGen Pharma Corp. Fundamental data includes:
- Net Revenue:
- EBITDA: -26 519 752
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-18
- EPS/Forecast: -0.0585
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NervGen Pharma Corp. News
New
NervGen Pharma prices 24M share public offering; warrants exercisable at $3.68
NervGen Pharma (NGEN [https://seekingalpha.com/symbol/NGEN]) has announced pricing of a public offering [https://seekingalpha.com/pr/20525704-nervgen-announces-pricing-of-us-60_0-million-public-offeri...
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-c...
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in...
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company develop...
Get NervGen Pharma Corp. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
